

---

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(Amendment No. 1)\*

**Neumora Therapeutics, Inc.**

---

(Name of Issuer)

**Common Stock, par value \$0.0001 per share**

---

(Title of Class of Securities)

---

(CUSIP Number)

**03/31/2026**

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

---

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Invus Public Equities, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

BERMUDA

Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power  
7,740,030.00  
Shared Voting Power  
6  
0.00  
Sole Dispositive Power  
7  
7,740,030.00  
Shared Dispositive Power  
8  
0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

7,740,030.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

4.3 %

Type of Reporting Person (See Instructions)

PN

**SCHEDULE 13G**

**CUSIP No.**

Names of Reporting Persons

Invus Public Equities Advisors, LLC

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Sole Voting Power

5  
7,740,030.00

Shared Voting Power

6  
0.00

Sole Dispositive Power

7  
7,740,030.00

Shared Dispositive Power

8  
0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

7,740,030.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11 Percent of class represented by amount in row (9)

4.3 %

Type of Reporting Person (See Instructions)

12

OO

## SCHEDULE 13G

### CUSIP No.

Names of Reporting Persons

1

Invus Global Management, LLC

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

7,740,030.00

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person  
With:

Shared Voting Power

6

0.00

Sole Dispositive Power

7

7,740,030.00

Shared Dispositive

8

Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

7,740,030.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

4.3 %

Type of Reporting Person (See Instructions)

12

OO

## SCHEDULE 13G

### CUSIP No.

Names of Reporting Persons

1

Siren, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3 Sec Use Only  
Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5

7,740,030.00

Number of Shares Beneficially Owned by Each Reporting Person With:

Shared Voting Power

6

0.00

Sole Dispositive Power

7

7,740,030.00

Shared Dispositive

8

Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

7,740,030.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

4.3 %

Type of Reporting Person (See Instructions)

12

OO

## SCHEDULE 13G

### CUSIP No.

Names of Reporting Persons

1

Avicenna Life Sci Master Fund LP

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3 Sec Use Only

Citizenship or Place of Organization

4

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

Sole Voting Power

5

757,792.00

Shared Voting Power

6

0.00

Sole Dispositive Power

7

757,792.00

8 Shared Dispositive Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

757,792.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.4 %

Type of Reporting Person (See Instructions)

12

PN

### SCHEDULE 13G

#### CUSIP No.

Names of Reporting Persons

1

Avicenna Life Sci Master GP LLC

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

757,792.00

Number of  
Shares

Shared Voting Power

Beneficially

6

0.00

Owned by

Sole Dispositive Power

Each

7

757,792.00

Reporting  
Person

Shared Dispositive

With:

8

Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

757,792.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.4 %

Type of Reporting Person (See Instructions)

12

OO

### SCHEDULE 13G

**CUSIP No.**

Names of Reporting Persons

1

Ulys, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

757,792.00

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person  
With:

6

Shared Voting Power

0.00

7

Sole Dispositive Power

757,792.00

8

Shared Dispositive

Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

757,792.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.4 %

Type of Reporting Person (See Instructions)

12

OO

**SCHEDULE 13G**

**CUSIP No.**

Names of Reporting Persons

1

Raymond Debbane

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

PANAMA

Sole Voting Power

5

8,497,822.00

Number of  
Shares  
Beneficially  
Owned by  
Each

6

Shared Voting Power

Reporting

Person 0.00  
With: Sole Dispositive Power  
7  
8,497,822.00  
Shared Dispositive  
8 Power  
0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

8,497,822.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)



Percent of class represented by amount in row (9)

4.7 %

Type of Reporting Person (See Instructions)

IN

### SCHEDULE 13G

Item 1.

Name of issuer:

(a) Neumora Therapeutics, Inc.

Address of issuer's principal executive offices:

(b) 260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 02472

Item 2.

Name of person filing:

(a) See Item 2(c) below.

Address or principal business office or, if none, residence:

(b) See Item 2(c) below.

Citizenship:

(c) (i) Invus Public Equities, L.P. ("Invus Public Equities") 750 Lexington Avenue, 30th Floor, New York, NY 10022  
Citizenship: Bermuda limited partnership (ii) Invus Public Equities Advisors, LLC ("Invus PE Advisors") 750  
Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (iii) Invus  
Global Management, LLC ("Global Management") 750 Lexington Avenue, 30th Floor, New York, NY 10022  
Citizenship: Delaware limited liability company (iv) Siren, L.L.C. ("Siren") c/o The Invus Group, LLC, 750  
Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (v) Avicenna  
Life Sci Master Fund LP ("Avicenna Fund") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship:  
Cayman Islands limited partnership (vi) Avicenna Life Sci Master GP LLC ("Avicenna GP") 750 Lexington Avenue,  
30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (vii) Ulys, L.L.C. ("Ulys") 750  
Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (viii) Mr.  
Raymond Debbane 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Panama The foregoing  
persons are hereinafter sometimes collectively referred to as the "Reporting Persons."

Title of class of securities:

(d) Common Stock, par value \$0.0001 per share

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k)  Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

As of March 31, 2026, Invus Public Equities directly held 7,740,030 shares of common stock, par value \$0.0001 per share (the "Shares") of Neumora Therapeutics, Inc. (the "Issuer"), and Avicenna Fund directly held 757,792 Shares of the Issuer. Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares directly held by Invus Public Equities. Global Management, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Siren, as the managing member of Global Management, controls Global Management and, accordingly, may be deemed to beneficially own the Shares that Global Management may be deemed to beneficially own. Avicenna GP, as the general partner of Avicenna Fund, controls Avicenna Fund and, accordingly, may be deemed to beneficially own the Shares directly held by Avicenna Fund. Ulys, as the managing member of Avicenna GP, controls Avicenna GP and, accordingly, may be deemed to beneficially own the Shares that Avicenna GP may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren and Ulys, controls Siren and Ulys and, accordingly, may be deemed to beneficially own the Shares that Siren and Ulys may be deemed to beneficially own.

Percent of class:

- (a) As of March 31, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person's cover page. Calculations of the percentage of Shares beneficially owned are based on 182,040,945 Shares outstanding as of March 23, 2026, based on information provided by the Issuer in its annual report on Form 10-K as filed with the Securities and Exchange Commission on March 30, 2026. %

- (c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See each cover page hereof.

(ii) Shared power to vote or to direct the vote:

See each cover page hereof.

(iii) Sole power to dispose or to direct the disposition of:

See each cover page hereof.

(iv) Shared power to dispose or to direct the disposition of:

See each cover page hereof.

Item 5. Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Item 10. Certifications:

Each of the Reporting Persons hereby makes the following certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Invus Public Equities, L.P.

Signature: /s/ Raymond Debbane  
Name/Title: Raymond Debbane, President of Invus Public  
Equities Advisors, LLC, its general partner  
Date: 05/04/2026

Invus Public Equities Advisors, LLC

Signature: /s/ Raymond Debbane  
Name/Title: Raymond Debbane, President  
Date: 05/04/2026

Invus Global Management, LLC

Signature: /s/ Raymond Debbane  
Name/Title: Raymond Debbane, President  
Date: 05/04/2026

Siren, L.L.C.

Signature: /s/ Raymond Debbane  
Name/Title: Raymond Debbane, President  
Date: 05/04/2026

Avicenna Life Sci Master Fund LP

Signature: /s/ Raymond Debbane  
Raymond Debbane, Chief Executive Officer of  
Name/Title: Avicenna Life Sci Master GP LLC, its general  
partner  
Date: 05/04/2026

Avicenna Life Sci Master GP LLC

Signature: /s/ Raymond Debbane  
Name/Title: Raymond Debbane, Chief Executive Officer  
Date: 05/04/2026

Ulys, L.L.C.

Signature: /s/ Raymond Debbane  
Name/Title: Raymond Debbane, President  
Date: 05/04/2026

Raymond Debbane

Signature: /s/ Raymond Debbane  
Name/Title: Raymond Debbane  
Date: 05/04/2026